Sutro Biopharma, Inc. (STRO) income statement

STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$9.82+0.23 (+2.40%)

Close on Nov 13, 2026Market cap $162.83MP/E –Yield –

Sutro Biopharma, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	102	62	154	68	62	43	43	38	52	60
Research & Development	166	252	180	137	104	77	66	54	55	44
General & Administrative	41	48	63	60	56	37	33	21	16	15
Operating Expenses	261	300	243	197	160	114	98	76	71	58
Operating Income	-158	-238	-89	-129	-99	-71	-55	-37	-19	1.36
Interest Expense	–	–	1.30	2.40	2.60	2.30	1.10	1.60	0.60	0
Other Non-Operating Income	–	–	–	–	–	–	–	1.91	-0.08	0.09
Merger & Restructuring Charges	13	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	1.69	0	–	–	–	–	–	0	2.74	0
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	-0.28	–	–	–
Pretax Income	-191	-225	-89	-117	-106	-32	–	–	–	–
Income Tax Expense	-0.09	2.36	18	2.50	0	0.10	0	0	0	–
Net Income incl. Noncontrolling Interests	-191	-227	-107	-119	-106	-32	-56	-35	-20	1.70
Net Income	-191	-227	-107	-119	-106	-32	-119	-35	-20	1.70
EPS (Basic)(per share)	-22.49	-29.40	-17.80	-23.50	-22.90	-9.90	-24.30	-61.30	-439.50	0.00
EPS (Diluted)(per share)	-22.49	-29.40	-17.80	-23.50	-22.90	-9.90	-24.30	-61.30	-439.50	0.00
Shares Outstanding (Basic, Weighted)(shares)	8.50	7.74	6.02	5.07	4.61	3.26	2.30	0.58	0.04	0.04
Shares Outstanding (Diluted, Weighted)(shares)	8.50	7.74	6.02	5.07	4.61	3.26	2.30	0.58	0.04	0.04
EBITDA	-151	-231	-82	-123	-94	-67	-51	-33	-14	7.03
Net Interest Income	–	–	–	–	–	–	-4.35	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -265.0%
Net margin: -344.2%
Return on equity, FY2025: 435.0%

Financial strength

Current ratio: 2.94
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 86.3%

Valuation

P/E ratio: –
Price to sales: 3.61
Price to book: –
Dividend yield: –

See a number that looks wrong?